Exploiting Carbon Monoxide Biofoams to Radio-Sensitize Rectal Cancer Cells While Protecting Normal Bowel

利用一氧化碳生物泡沫对直肠癌细胞放射增敏，同时保护正常肠道

基本信息

批准号：
10572013
负责人：
James Donald Byrne
金额：
$ 25.32万
依托单位：
UNIVERSITY OF IOWA
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-06-09 至 2028-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10572013
关键词：
Acute Adjuvant Therapy Antioxidants Antitumor Response Biochemical Biocompatible Materials Biology Cancer Biology Cancer Patient Carbon Monoxide Catabolism Cell Respiration Cell Survival Cells Cellular biology Chronic Colorectal Cancer Combination Drug Therapy Cytoprotection Diagnosis Dose Doxycycline Environment Epithelial Cells Evaluation Excision Exposure to Formulation Free Radicals Gastrointestinal tract structure Genes Genetic Goals Heme Hydrogen Peroxide In Vitro Incidence Individual Inflammation Inhalation International Intestines Iowa Knockout Mice Lead Malignant Neoplasms Mentors Metabolic Methodology Methods Mitochondria Modeling Molecular Molecular Biology Mus Neoadjuvant Therapy Normal Cell Normal tissue morphology Operative Surgical Procedures Oxidation-Reduction Oxidative Stress Oxidative Stress Induction Pathologic Processes Pathway interactions Physicians Physiological Processes Positioning Attribute Proctitis Production Property Quality of life Quantitative Evaluations Radiation Radiation Tolerance Radiosensitization Rectal Cancer Rectum Regimen Research Role Scientist Severity of illness Signal Transduction Stress Superoxides Testing Therapeutic Tissues Training Translating Translations Tumor Burden Tumor Tissue United States Universities Work anti-cancer antioxidant enzyme antitumor effect biological adaptation to stress biomaterial development cancer cell cell killing chemoradiation enzyme pathway gastrointestinal heme oxygenase-1 improved improved outcome in vivo intestinal epithelium mimetics mouse model neoplastic cell novel novel therapeutics oxidative damage pharmacologic preservation radiation response rectal response skills tissue injury tool transcription factor translational therapeutics

项目摘要

ABSTRACT An estimated 45,230 individuals were diagnosed with rectal cancer in the United States in 2021. Rectal cancer is primarily managed using a combination of chemotherapy, radiation, and surgery. Surgical resection of the rectum is associated with long-term functional deficits and decreased quality-of-life. Therefore, strategies to improve response to neoadjuvant chemoradiotherapy could increase non-surgical curative rates and enhance quality-of-life for rectal cancer patients. Carbon monoxide (CO) at low, non-toxic concentrations has been shown to provide paradoxical anti-tumor effects while inhibiting inflammation and oxidative-stress induced normal tissue injury that could serve as an adjuvant treatment to enhance chemo-radiotherapy efficacy. CO is a product of heme catabolism regulated by the Nrf2 transcription factor and the cytoprotective gene Heme Oxygenase-1 (HO- 1). The biochemical mechanisms by which CO simultaneously sensitizes tumor cells to die while preserving normal cell survival are unknown but likely involve fundamental differences in oxidative metabolism between cancer and normal cells. Identifying targetable redox sensitive mechanisms underlying the activity of CO in rectal cancer could rapidly lead to translational therapeutic approaches for improving radiation responses in cancers while limiting normal tissue injury. We have developed exciting new methods for CO delivery through the gastrointestinal (GI) tract to overcome the challenges of inhaled CO. Using these GI formulations to deliver CO, our central hypothesis is that CO, delivered as a safe biofoam, selectively chemo-radio-sensitizes rectal cancer while reducing normal tissue injury. Further that the mechanism involves differential effects on Nrf2/HO-1 signaling and modulation of mitochondrial oxidative metabolism. We will evaluate the impact of cytoprotective CO biofoams on normal rectal tissue responses and oxidative damage after exposure to chemoradiotherapy and determine the effects of CO as an adjunct to therapy for rectal cancer in mice.

抽象的估计在2021年美国被诊断出45,230名直肠癌。直肠癌。主要使用化学疗法，放射线和手术的组合来管理。手术切除直肠与长期功能缺陷和生活质量降低有关。因此，策略改善对新辅助化学放射治疗的反应可能会提高非手术治疗率并提高直肠癌患者的生活质量。已经显示了低毒性浓度的一氧化碳（CO）提供矛盾的抗肿瘤作用，同时抑制炎症和氧化诱导的正常组织可以用作辅助治疗的损伤，以增强化学疗法疗法。 CO是由NRF2转录因子和细胞保护基因血红素氧酶1（HO-- 1）。 CO同时使肿瘤细胞死亡的生化机制在保存的同时敏感正常的细胞存活未知，但可能涉及氧化代谢的基本差异癌症和正常细胞。确定CO在直肠活动中的活性基础的可靶向氧化还原敏感机制癌症可能会迅速导致转化治疗方法，以改善癌症的辐射反应同时限制正常组织损伤。我们开发了令人兴奋的新方法，用于通过胃肠道（GI）道以克服吸入CO的挑战。使用这些GI公式提供CO，我们的中心假设是，CO（作为安全的生物卵石传递）有选择地化学性化学敏感性直肠癌症同时减少正常组织损伤。此外，该机制涉及对 NRF2/HO-1信号传导和线粒体氧化代谢的调节。我们将评估暴露于正常直肠组织反应和氧化损伤后的细胞保护co生物膜。化学放疗，并确定CO作为小鼠直肠癌治疗的辅助作用。